Showing results (171-180 of 281) with videos related to

Sort By:
Pageof 29
Clinical Pharmacology and Therapeutics|October 11, 2017
Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working GroupP C D Bank, K E Caudle, J J Swen, et al.
Pharmacogenetics|July 31, 1998
Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individualsH L McLeod, A C Syvänen, J Githang'a, et al.
The Journal of Clinical Investigation|November 1, 1994
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemiaT W Synold, M V Relling, J M Boyett, et al.
Leukemia|October 10, 1998
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemiaM H Woo, L J Hak, M C Storm, et al.
British Journal of Clinical Pharmacology|September 6, 2000
Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populationsJ M Morsman, J Sludden, M M Ameyaw, et al.
Blood|February 25, 1999
Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulationV M Belkov, E Y Krynetski, J D Schuetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemiaM H Woo, L J Hak, M C Storm, et al.
International Journal of Cancer|August 30, 2000
Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal InitiativeJ A McKay, J J Douglas, V G Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphomaC H Pui, H H Mahmoud, J M Wiley, et al.
Clinical Pharmacology and Therapeutics|August 8, 2008
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemiaG Stocco, M H Cheok, K R Crews, et al.
Pageof 29